NASDAQ:ACET - Aceto Stock Price, News, Headlines & Rumors Sign in or create an account to add this stock to your watchlist. Get Started $3.21 -0.02 (-0.62 %) (As of 08/16/2018 04:00 PM ET)Previous Close$3.23Today's Range$3.19 - $3.3152-Week Range$2.22 - $16.51Volume164,706 shsAverage Volume594,427 shsMarket Capitalization$96.67 millionP/E Ratio2.70Dividend Yield1.27%Beta1.62 Company ProfileAnalyst RatingsChartDividend HistoryEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Aceto Corporation, together with its subsidiaries, sources, markets, sells, and distributes finished dosage form generics, nutraceutical products, pharmaceutical intermediates and active ingredients, agricultural protection products, and specialty chemicals. The company operates in three segments: Human Health, Pharmaceutical Ingredients, and Performance Chemicals. The Human Health segment supplies raw materials used in the production of nutritional and packaged dietary supplements, including vitamins, amino acids, iron compounds, and bio chemicals used in pharmaceutical and nutritional preparations. This segment is also involved in developing and marketing generic pharmaceutical products. It sells its generic prescription and over the counter pharmaceutical products to wholesalers, chain drug stores, distributors, and mass market merchandisers. The Pharmaceutical Ingredients segment offers active pharmaceutical ingredients and pharmaceutical intermediates to various generic drug companies. The Performance Chemicals segment provides specialty chemicals for use in the manufacture of plastics, surface coatings, cosmetics and personal care products, textiles, and fuels and lubricants, as well as for food, flavor, paper, and film industries; dye and pigment intermediates used in the color-producing industries; and organic intermediates used in the production of agrochemicals. Its raw materials are also used in electronic parts for photo tooling, circuit boards, and production of computer chips. This segment also offers agricultural protection products comprising herbicides, fungicides, and insecticides, which control weed growth and the spread of insects and microorganisms; and sprout inhibitors for potatoes. The company serves various companies in the industrial chemical, agricultural, and human health and pharmaceutical industries primarily in the United States, Europe, and Asia. Aceto Corporation was founded in 1947 and is headquartered in Port Washington, New York. Receive ACET News and Ratings via Email Sign-up to receive the latest news and ratings for ACET and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Drugs, proprietaries, & sundries Sub-IndustryTrading Companies & Distributors SectorMedical SymbolNASDAQ:ACET CUSIP00444610 Webwww.aceto.com Phone516-627-6000 Debt Debt-to-Equity Ratio0.63 Current Ratio1.12 Quick Ratio0.80 Price-To-Earnings Trailing P/E Ratio2.70 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$638.32 million Price / Sales0.15 Cash Flow$2.4884 per share Price / Cash1.29 Book Value$13.54 per share Price / Book0.24 Profitability EPS (Most Recent Fiscal Year)$1.19 Net Income$11.37 million Net Margins-28.23% Return on Equity7.93% Return on Assets2.88% Miscellaneous Employees286 Outstanding Shares30,790,000Market Cap$96.67 million Aceto (NASDAQ:ACET) Frequently Asked Questions What is Aceto's stock symbol? Aceto trades on the NASDAQ under the ticker symbol "ACET." How often does Aceto pay dividends? What is the dividend yield for Aceto? Aceto announced a quarterly dividend on Thursday, May 3rd. Investors of record on Friday, June 8th will be paid a dividend of $0.01 per share on Friday, June 22nd. This represents a $0.04 annualized dividend and a dividend yield of 1.25%. The ex-dividend date of this dividend is Thursday, June 7th. View Aceto's Dividend History. How were Aceto's earnings last quarter? Aceto Co. (NASDAQ:ACET) released its earnings results on Thursday, May, 3rd. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.23 by $0.22. The firm earned $186 million during the quarter. Aceto had a positive return on equity of 7.93% and a negative net margin of 28.23%. During the same quarter in the previous year, the company earned $0.39 earnings per share. View Aceto's Earnings History. When is Aceto's next earnings date? Aceto is scheduled to release their next quarterly earnings announcement on Thursday, August, 23rd 2018. View Earnings Estimates for Aceto. What price target have analysts set for ACET? 2 equities research analysts have issued twelve-month price objectives for Aceto's shares. Their forecasts range from $2.00 to $2.00. On average, they anticipate Aceto's share price to reach $2.00 in the next year. This suggests that the stock has a possible downside of 37.7%. View Analyst Price Targets for Aceto. What is the consensus analysts' recommendation for Aceto? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aceto in the last year. There are currently 2 sell ratings for the stock, resulting in a consensus recommendation of "Sell." View Analyst Ratings for Aceto. What are Wall Street analysts saying about Aceto stock? Here are some recent quotes from research analysts about Aceto stock: 1. Canaccord Genuity analysts commented, "We are pleased with the appointment of Ed Borkowski as chief financial officer, as he brings a breadth of generics knowledge and experience that will likely help Aceto’s continued transition into a human health company. We like the turnaround potential for Aceto, but believe management will need to execute for a number of quarters before generating meaningful investor interest; we maintain our BUY rating on ACET shares. Roth’s retirement has been well telegraphed in parallel to the on-boarding of William Kennally as CEO. Douglas Roth has been CFO since 2001, and was a key leader in the transformation of Aceto from specialty chemicals/API to human health. After the appointment of Bill Kennally as CEO late last year, we expected Aceto to find a thoughtful, seasoned finance leader to complement Kennally’s experience, and see Borkowski as an excellent add." (2/16/2018) 2. According to Zacks Investment Research, "Aceto Corporation markets, sells and distributes finished dosage form generics, nutraceutical products, pharmaceutical intermediates and active ingredients, agricultural protection products and specialty chemicals. The company's operating segment consists of Human Health, Pharmaceutical Ingredients and Performance Chemicals. Human Health segment supplies raw materials used in the production of nutritional and packaged dietary supplements. It markets and distributes its generic prescription and over the counter pharmaceutical products. Pharmaceutical Ingredients segment offers active pharmaceutical ingredients and pharmaceutical intermediates. Performance Chemicals segment provides specialty chemicals. It serves chemical, agricultural, human health and pharmaceutical industries. The company operates primarily in United States, Europe, and Asia. Aceto Corporation and is headquartered in Port Washington, New York. " (2/6/2018) Who are some of Aceto's key competitors? Some companies that are related to Aceto include McKesson (MCK), AmerisourceBergen (ABC), Cardinal Health (CAH), Herbalife Nutrition (HLF), Nu Skin Enterprises (NUS), PetIQ (PETQ), Trxade Group (TRXD), biOasis Technologies (BIOAF) and Medizone International (MZEI). Who are Aceto's key executives? Aceto's management team includes the folowing people: Mr. William C. Kennally III, Pres, CEO & Director (Age 63)Mr. Walter J. Kaczmarek III, Chief Operating Officer (Age 59)Mr. Frank DeBenedittis, SVP of Corp. Bus. Devel. & International SVP of Active Pharmaceutical Ingredients (Age 64)Ms. Rebecca A. Roof, Interim Chief Financial Officer (Age 62)Ms. Frances P. Scally, Chief Accounting Officer (Age 51) Has Aceto been receiving favorable news coverage? Headlines about ACET stock have trended somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Aceto earned a daily sentiment score of 0.22 on Accern's scale. They also gave news stories about the company an impact score of 46.08 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future. View Recent Headlines for Aceto. Who are Aceto's major shareholders? Aceto's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.36%), Dimensional Fund Advisors LP (8.25%), Renaissance Technologies LLC (1.64%), Royce & Associates LP (1.58%), Connor Clark & Lunn Investment Management Ltd. (1.30%) and Bank of New York Mellon Corp (1.28%). Company insiders that own Aceto stock include Albert L Eilender, Charles John Alaimo, Daniel B Yarosh, Douglas A Roth, Frances P Scally, Frank Debenedittis, Hans C Noetzli, Nicolas I Shackley, Raymond Bartone, Salvatore J Sr Guccione Sr, Satish Srinivasan, Steven Rogers and Walter J Kaczmarek III. View Institutional Ownership Trends for Aceto. Which institutional investors are selling Aceto stock? ACET stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, BlackRock Inc., Royce & Associates LP, Schwab Charles Investment Management Inc., Dimensional Fund Advisors LP and Rhumbline Advisers. Company insiders that have sold Aceto company stock in the last year include Albert L Eilender, Charles John Alaimo, Frances P Scally, Frank Debenedittis, Salvatore J Sr Guccione Sr, Steven Rogers and Walter J Kaczmarek III. View Insider Buying and Selling for Aceto. Which institutional investors are buying Aceto stock? ACET stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Connor Clark & Lunn Investment Management Ltd., Paloma Partners Management Co, Los Angeles Capital Management & Equity Research Inc., LMR Partners LLP, OppenheimerFunds Inc., Hartford Investment Management Co. and Jane Street Group LLC. View Insider Buying and Selling for Aceto. How do I buy shares of Aceto? Shares of ACET can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Aceto's stock price today? One share of ACET stock can currently be purchased for approximately $3.21. How big of a company is Aceto? Aceto has a market capitalization of $96.67 million and generates $638.32 million in revenue each year. The company earns $11.37 million in net income (profit) each year or $1.19 on an earnings per share basis. Aceto employs 286 workers across the globe. How can I contact Aceto? Aceto's mailing address is 4 TRI HARBOR COURT, PORT WASHINGTON NY, 11050. The company can be reached via phone at 516-627-6000 or via email at [email protected] MarketBeat Community Rating for Aceto (NASDAQ ACET)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 170 (Vote Outperform)Underperform Votes: 174 (Vote Underperform)Total Votes: 344MarketBeat's community ratings are surveys of what our community members think about Aceto and other stocks. Vote "Outperform" if you believe ACET will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACET will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 8/16/2018 by MarketBeat.com StaffFeatured Article: What kind of dividend yield to CEF's pay?